{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:43:20Z","timestamp":1787579000165,"version":"build-2736575974"},"reference-count":11,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,12]]},"abstract":"<jats:title\/>\n               <jats:p>COVID-19 still represents a major issue for patients with lymphoid malignancies, especially those on therapy, because of immune suppression and suboptimal responses to vaccination. Davis et al report on their experience with double dose tixagevimab-cilgavimab preexposure prophylaxis in a cohort of 251 patients with chronic lymphocytic leukemia, B-cell lymphomas, multiple myeloma, or B-cell acute lymphoblastic leukemia, 63% of whom had received 3 doses of the SARS-CoV-2 vaccine. Breakthrough infections within 3 months occur despite passive immunization, affecting 11% in this series; however, hospitalization rates are low, and mortality was avoided, suggesting benefit from this strategy.<\/jats:p>","DOI":"10.1182\/blood.2022018283","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T20:07:27Z","timestamp":1667592447000},"page":"200-203","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":50,"title":["Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"first","affiliation":[{"name":"1Department of Pharmacy, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelynn","family":"Granger","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiera","family":"Roubal","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-4433","authenticated-orcid":false,"given":"Deidra","family":"Smith","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9280-4502","authenticated-orcid":false,"given":"Kelly J.","family":"Gaffney","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-6573","authenticated-orcid":false,"given":"Mary","family":"McGann","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Cendagorta","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswani","family":"Thurlapati","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Herbst","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Hendrickson","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-5867","authenticated-orcid":false,"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hess","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2023082419143288200_bib1","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2023082419143288200_bib2","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2023082419143288200_bib3","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Scarf\u00f2","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"2023082419143288200_bib4","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood.2021014124","article-title":"COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA","volume":"139","author":"Pagano","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2023082419143288200_bib5","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"key":"2023082419143288200_bib6","author":"Evusheld","year":"2022"},{"issue":"23","key":"2023082419143288200_bib7","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular azd7442 (Tixagevimab-cilgavimab) for prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2023082419143288200_bib8","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"2023082419143288200_bib9","unstructured":"South Carolina COVID-19 Variant Proportions\n          . South Carolina Department of Health and Environmental Control. September 2022. Accessed 26 September 2022. https:\/\/scdhec.gov\/covid19\/covid-19-variants."},{"issue":"6","key":"2023082419143288200_bib10","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccell.2022.05.007","article-title":"Activity of AZD7442 (Tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies","volume":"40","author":"Stuver","year":"2022","journal-title":"Cancer Cell"},{"key":"2023082419143288200_bib11","doi-asserted-by":"crossref","unstructured":"Nguyen\n              Y.\n            , FlahaultA., ChavarotN., . Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld\u00a9) for COVID-19 among 1112 severely immunocompromised patients [published online ahead of print 1 August 2022]. Clin Microbiol Infect. https:\/\/doi.org\/10.1016\/j.cmi.2022.07.015.","DOI":"10.1016\/j.cmi.2022.07.015"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/2\/200\/2073186\/blood_bld-2022-018283-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/2\/200\/2073186\/blood_bld-2022-018283-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T19:15:31Z","timestamp":1692904531000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/2\/200\/487026\/Efficacy-of-tixagevimab-cilgavimab-in-preventing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022018283","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]}}}